Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
Follow SEPN
Alert me
Septerna, Inc. (SEPN) EV/FCF
As of 5 November 2026, Septerna, Inc. (SEPN) trades at a EV/FCF of 15.2×. Over the past ten years it has ranged from −5.7× (September 2025) to 15.3× (August 2026); the current reading is higher than 100% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 6.9× | 160.32% |
| FY2024 | 2.7× | 19.96% |
| FY2023 | 2.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 9.7× | 58.45% |
| Mar 2026 | 6.1× | (11.62%) |
| Dec 2025 | 6.9× | 121.79% |
| Sep 2025 | 3.1× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| ZYME Zymeworks Inc. compare | −15.1× |
| IMNM Immunome, Inc. compare | −7.0× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.6× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| SEPN Septerna, Inc. | 15.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement